24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
CISLIEVA 50MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | CISLIEVA 50MG |
|---|---|
| Composition | Cisplatin Injection IP 50mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
CISLIEVA 50MG (Cisplatin Injection IP 50mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
CISLIEVA 50 MG (Cisplatin Injection IP 50 mg) is a prescription anticancer medicine containing Cisplatin 50 mg, a platinum-based chemotherapy agent widely used in the treatment of various solid tumors. Cisplatin belongs to the class of medicines known as Platinum Coordination Compounds, which work by damaging the DNA of cancer cells, thereby preventing their growth, replication, and spread.
Cisplatin is one of the most extensively used chemotherapy medicines in oncology and has been a cornerstone of cancer treatment for several decades. It interferes with cancer cell DNA by forming cross-links within DNA strands, making it difficult for cancer cells to divide and survive. This ultimately leads to cancer cell death and helps control tumor progression.
CISLIEVA 50 MG is commonly prescribed as part of single-agent or combination chemotherapy regimens for a wide range of cancers. It is frequently used in treatment protocols for testicular cancer, ovarian cancer, bladder cancer, lung cancer, head and neck cancer, cervical cancer, and other solid tumors.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
CISLIEVA 50 MG is commonly used for:
Manufactured according to stringent pharmaceutical quality standards, CISLIEVA 50 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Cisplatin therapy require regular monitoring of kidney function, liver function, hearing, electrolyte levels, and blood counts to ensure safe and effective treatment.
Due to its broad clinical utility and proven effectiveness, CISLIEVA 50 MG remains a key medicine in modern cancer treatment.
CISLIEVA 50 MG (Cisplatin Injection IP 50 mg) is primarily used in the treatment and management of various cancers.
Cisplatin is a cornerstone treatment in many testicular cancer chemotherapy regimens.
The medicine is commonly used in advanced and recurrent ovarian cancer treatment.
Doctors may prescribe Cisplatin as part of combination chemotherapy protocols for bladder cancer.
Cisplatin is widely used in both small cell and non-small cell lung cancer treatment.
The medicine is frequently used alongside radiation therapy and other anticancer medicines.
Cisplatin may be administered as part of chemoradiation treatment programs.
The medicine is incorporated into treatment protocols for several additional cancer types.
Cisplatin belongs to a class of medicines known as Platinum-Based Anticancer Agents.
CISLIEVA works by:
This mechanism helps control cancer development and supports effective disease management.
Like all medicines, CISLIEVA 50 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Digestive discomfort is among the most commonly reported side effects.
Weakness and tiredness may occur during treatment.
Reduced appetite may affect nutritional intake.
Cisplatin may affect kidney function and requires regular monitoring.
The medicine may reduce white blood cells, red blood cells, and platelets.
Some patients may experience hearing impairment or ringing in the ears (tinnitus).
Changes in magnesium, potassium, and calcium levels may occur.
Numbness, tingling, or nerve-related symptoms may develop.
Lower white blood cell counts may increase susceptibility to infections.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of CISLIEVA 50 MG (Cisplatin Injection IP 50 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to the cancer being treated.
Dosage is generally calculated according to body surface area.
Renal function is a critical factor in dosage planning.
Combination chemotherapy regimens may influence dosage schedules.
Blood counts and electrolyte levels help guide treatment decisions.
Before starting treatment, inform your doctor if you have:
Patients receiving Cisplatin therapy may require:
Patients should also disclose all prescription medicines, supplements, vitamins, and herbal products they are taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically advised by a healthcare professional.
It is used for the treatment of testicular cancer, ovarian cancer, bladder cancer, lung cancer, head and neck cancer, cervical cancer, and other solid tumors.
Cisplatin is a platinum-based chemotherapy medicine that damages cancer cell DNA and prevents tumor growth.
Yes. Cisplatin is one of the most widely used platinum-based chemotherapy agents.
Hydration helps reduce the risk of kidney-related side effects associated with Cisplatin therapy.
Yes. Hearing changes, including tinnitus and hearing loss, may occur and require monitoring.
Yes. Kidney monitoring is essential throughout treatment.
Yes. The medicine may lower white blood cells, red blood cells, and platelet counts.
Yes. This medicine should only be administered by qualified healthcare professionals experienced in oncology treatment.